A bipartisan group of U.S. representatives is seeking answers about why the federal government is seemingly favoring foreign marijuana suppliers while stalling the approval of additional domestic cannabis producers.

In a letter addressed to the acting administrator of the Drug Enforcement Administration (DEA) and U.S. Attorney General Jeff Sessions, 15 members of Congress, led by Reps. Matt Gaetz (R-FL) and Eric Swalwell (D-CA), expressed “deep concern” over the delay in reviewing and approving domestic cultivators of marijuana for research purposes.

Since 1968, there has been just one supplier of marijuana for research purposes in the United States—the University of Mississippi. In August 2016, the DEA announced a change in policy—”designed to foster research”—to allow more domestic entities to grow and distribute cannabis for research purposes.

But despite Sessions’s statement, some lawmakers are accusing the Department of Justice (DOJ) of stalling the review of at least 26 applications submitted to the DEA by would-be domestic marijuana suppliers. “Unfortunately, in the two years since DEA’s new policy, no additional manufacturers have been approved,” the U.S. representatives wrote in the Friday letter.

Meanwhile, on September 18, the DEA granted approval of the importation of cannabis capsules from Tilray Inc., a Canadian company, to supply research conducted by the Center for Medical Cannabis Research at the University of California San Diego.

This illustrated the “need for additional domestic manufacturers of marijuana for research purposes,” the lawmakers wrote. “The one manufacturer in the U.S. does not offer capsules of cannabis compounds. If there were other domestic manufacturers, they might offer this option.”

In the new joint letter, the representatives point to the hypocrisy of Trump’s executive order to “Buy American and Hire American” while American marijuana suppliers awaiting approval continue to go ignored.

Members of Congress have pressed the DEA and the DOJ for answers since the agency began accepting cultivation license applications. They argue that limiting the domestic supply of marijuana for research purposes is detrimental to a greater understanding of marijuana’s effects on health and society.

“Research on marijuana is necessary to resolve critical questions of public health and safety, such as learning the impacts of marijuana on developing brains and formulating methods to test marijuana impairment in drivers,” Sens. Kamala Harris (D-CA) and Orrin Hatch (R-UT) wrote in a separate letter to Sessions in April.

SIGN UP FOR NEWS & GET VIP UPDATES

AGE (21+) RESTRICTED PRODUCTS. NO SALES THROUGH THIS SITE. Warning: These products contain cannabis, a Schedule I controlled substance. Keep out of reach of children and animals. Cannabis may only be possessed or consumed by persons 21 years of age or older unless the person is a qualified patient. Cannabis use while pregnant or breastfeeding may be harmful. Consumption of cannabis impairs your ability to drive and operate machinery. Please use extreme caution. California Proposition 65 Warning: Smoking this product will expose you and those in your immediate vicinity to marijuana smoke, a chemical known to the State of California to cause cancer.